Company's CypherAtlas™ database emerges as one of oncology's largest integrated dark transcriptome and proteome resources

公司旗下的CypherAtlas™数据库成为肿瘤学领域最大的综合暗转录组和蛋白质组资源之一。

SAN DIEGO

圣地亚哥

,

，

March 24, 2026

2026年3月24日

/PRNewswire/ -- RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed financing from a syndicate of new and existing investors. The financing will accelerate the company's transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.

/PRNewswire/ -- RyboDyn, Inc.是一家利用人工智能驱动的新型测序与发现平台解码暗蛋白质组的生物技术公司，今天宣布已完成由新老投资者组成的投资集团提供的1000万美元种子轮融资。这笔资金将加速公司从基础发现向规模化平台执行的过渡，并推动早期项目进入支持IND申请的研究阶段。

.

。

Continue Reading

继续阅读

RyboDyn founders Imad Ajjawi, PhD (left), and Corey Dambacher, PhD (right), at Lilly Gateway Labs in San Diego.

RyboDyn 创始人 Imad Ajjawi 博士（左）和 Corey Dambacher 博士（右）在圣地亚哥的 Lilly Gateway 实验室。

Oncology drug development is facing a paradox. While advances in AI and protein engineering are frequently touted as significantly accelerating drug design, the targets those drugs chase are more crowded than ever. For example, the well-known EGFR target has over 200 drugs approved or in development, and the PD-1/PD-L1 checkpoint axis has nearly 200 more.

肿瘤学药物开发正面临一个悖论。尽管人工智能和蛋白质工程的进步被频繁吹捧为显著加速了药物设计，但这些药物所追逐的靶点却比以往任何时候都更加拥挤。例如，著名的EGFR靶点已有200多种药物获批或正在开发中，而PD-1/PD-L1检查点轴还有近200种药物。

In an era of intense focus on AI-driven drug design, the bottleneck is no longer the ability to design high-affinity molecules. It's target discovery. The field needs new biology, and conventional genomics has largely run out of it..

在一个高度关注人工智能驱动药物设计的时代，瓶颈不再是设计高亲和力分子的能力。而是靶点发现。该领域需要新的生物学，而传统的基因组学在这方面基本上已经枯竭。

RyboDyn is looking somewhere else entirely.

里博戴恩正在完全不同的地方寻找。

For decades, much of the human genome, nearly 98%, was considered 'junk' DNA. We now know that some of these regions are transcriptionally active, yet they remain largely invisible to conventional sequencing approaches. RyboDyn has built the tools to decipher this hidden code to reveal novel biology.

几十年来，人类基因组的很大一部分（近 98%）被认为是“垃圾”DNA。我们现在知道其中一些区域具有转录活性，但它们对传统的测序方法而言仍然基本不可见。RyboDyn 已经开发出工具来解密这一隐藏代码，以揭示新的生物学机制。

The company is now translating these discoveries into actionable cancer targets to enable first-in-class therapies for patients with limited or no treatment options..

该公司现在正在将这些发现转化为可操作的癌症靶点，以期为治疗选择有限或无治疗选择的患者提供首创疗法。

At the core is RyboCypher™, the company's proprietary discovery engine, which combines deep sequencing of non-canonical RNAs with proteomic detection to identify disease-specific, druggable targets directly from patient tumors. These data are continuously integrated into CypherAtlas™, creating a proprietary, searchable atlas that powers foundational AI models to decode the dark proteome at scale..

核心是该公司的专有发现引擎 RyboCypher™，它结合了非经典 RNA 的深度测序与蛋白质组学检测，直接从患者肿瘤中识别疾病特异的、可成药的靶点。这些数据被持续整合到 CypherAtlas™ 中，创建出一个专有的、可搜索的地图集，为解码暗蛋白质组的基础 AI 模型提供支持。

Since announcing the discovery of a cryptic human proteome last year, initially demonstrated as proof-of-concept in cell line models, RyboDyn has rapidly expanded its proprietary CypherAtlas™ to include data from ~1,000 patient tumor samples across 10 distinct oncology indications. This expansion has driven the discovery from hundreds of thousands to more than 3 million conserved, novel dark (previously not characterized) RNAs, while increasing the number of cryptic peptides encoded by these dark RNA species by over two orders of magnitude.

自从去年宣布发现神秘的人类蛋白质组以来，这一概念最初在细胞系模型中作为概念验证展示，RyboDyn迅速扩展了其专有的CypherAtlas™，涵盖了来自10种不同肿瘤学适应症的约1,000例患者肿瘤样本的数据。这一扩展推动了从数十万到超过300万个保守的、新颖的暗RNA（之前未被表征）的发现，同时将这些暗RNA编码的隐秘肽数量增加了两个数量级以上。

Taken together, the CypherAtlas™ database now contains more than 80,000 cryptic peptides identified empirically by mass spectrometry, including ~15,000 cancer-specific peptides. Many of these proteins contain recognizable functional domains, suggesting roles as cryptic transcription factors, regulatory proteins, and novel cancer drivers that are frequently localized to the cell surface or secreted into the extracellular space.

综上所述，CypherAtlas™ 数据库现在包含超过 80,000 种通过质谱实证鉴定的隐秘肽，其中包括约 15,000 种癌症特异性肽。这些蛋白质中有许多包含可识别的功能域，表明它们可能作为隐秘转录因子、调节蛋白和新型癌症驱动因子发挥作用，且通常定位于细胞表面或分泌到细胞外空间。

Together, these features make them especially attractive therapeutic targets, with membrane-bound and focal adhesion-associated proteins emerging as high-priority opportunities for targeted immunotherapies. CypherAtlas™ is now the largest integrated dark transcriptome and proteome resource in the field, positioning the atlas as a one-of-a-kind engine for novel target discovery..

这些特性共同使它们成为极具吸引力的治疗靶点，其中膜结合蛋白和局灶黏附相关蛋白成为靶向免疫疗法的高优先级机会。CypherAtlas™ 目前是该领域最大的暗转录组和蛋白质组整合资源，使其成为独一无二的新靶点发现引擎。

'We set out to find the proteins that cancer hides behind, and we're now uncovering them at scale. RyboCypher™ and CypherAtlas™ provide a continuously expanding map of that hidden biology,' said Imad Ajjawi, PhD, MBA, CEO and Co-founder of RyboDyn. 'We're actively translating these discoveries into first-in-class therapies, both internally and with leading pharmaceutical partners.'.

“我们着手寻找癌症隐藏的蛋白质，现在我们正在大规模地揭示它们。RyboCypher™ 和 CypherAtlas™ 提供了不断扩展的隐藏生物学地图，”RyboDyn 的首席执行官兼联合创始人 Imad Ajjawi 博士、工商管理硕士说，“我们正在积极将这些发现转化为首创的治疗方法，既在公司内部进行，也与领先的制药合作伙伴共同推进。”

Critically, RyboDyn's novel cryptic targets represent an entirely uncontested target landscape. While established oncology targets each have hundreds of drugs in development, the therapies are inherently limited to patients who express those targets. HER2, for example, is present in only ~15-20% of breast cancer patients, leaving the majority of breast cancer patients without access to viable targeted immunotherapies.

关键是，RyboDyn的新型隐秘靶点代表了一个完全未被争夺的靶点领域。虽然已确立的肿瘤学靶点各自有数百种药物正在开发中，但这些疗法本质上仅限于表达这些靶点的患者。例如，HER2仅存在于约15-20%的乳腺癌患者中，使得大多数乳腺癌患者无法获得可行的靶向免疫疗法。

In contrast, RyboDyn's cryptic targets expand beyond conventional target space, enabling novel, tumor-specific therapies for broader patient populations..

相比之下，RyboDyn 的神秘靶点超越了传统的靶点空间，为更广泛的患者群体提供了新颖的肿瘤特异性治疗方法。

'It's clear that the molecules we're finding and describing for the first time represent a vast opportunity to tackle some of the most aggressive cancers,' said Dr. Corey Dambacher, President and Co-founder of RyboDyn. 'In a cohort of HER2-negative breast cancer patients, we identified a novel target present in approximately 45% of the tumors we analyzed.

“很明显，我们发现并首次描述的分子代表了一个应对一些最具侵袭性癌症的巨大机会，”RyboDyn公司总裁兼联合创始人科里·丹巴赫博士说道。“在一组HER2阴性的乳腺癌患者中，我们发现了一个新靶点，大约45%的我们分析的肿瘤中存在该靶点。”

Some of these are triple-negative patients with limited treatment options. That's the value proposition of our approach; the integration of RyboCypher™ with CypherAtlas™ allows us to identify entirely new, actionable targets.'.

其中一些是治疗选择有限的三阴性患者。这就是我们方法的价值主张；将RyboCypher™与CypherAtlas™整合，使我们能够识别出全新的、可操作的靶点。

The company has already demonstrated proof-of-concept in vitro, including the first-ever ADC-mediated killing of tumor cells via a cryptic protein target—a milestone that helped catalyze the current financing. 'RyboDyn is tackling one of the most underexplored frontiers in cancer biology,' said Eric Woersching, Managing Partner, at Massive Tech Ventures, a new institutional investor in the round.

该公司已经在体外展示了概念验证，包括通过隐蔽蛋白靶点首次实现ADC介导的肿瘤细胞杀伤——这一里程碑帮助推动了当前的融资。 Massive Tech Ventures的新机构投资者、管理合伙人埃里克·沃施宁表示：“RyboDyn正在攻克癌症生物学中最少被探索的前沿领域之一。”

'Their ability to systematically discover and validate targets from the dark proteome at this scale is highly differentiated. This new therapeutic landscape represents a fundamental shift in how cancer is targeted and RyboDyn is pioneering this shift.'.

“他们能够以这种规模系统地发现并验证来自暗蛋白质组的靶点，这一能力非常独特。这一新的治疗领域代表了癌症靶向方式的根本转变，而RyboDyn正是这一转变的先锋。”

About RyboDyn, Inc.

关于RyboDyn公司

RyboDyn

里博戴恩

is redefining how diseases are targeted by decoding a previously hidden human proteome; cryptic proteins missed by conventional and next-generation sequencing. Powered by RyboCypher™, its proprietary sequencing and AI platform, the company uncovers and validates novel, disease-specific cryptic targets to enable first-in-class antibody therapeutics for cancer and other diseases with high unmet medical need..

通过解码以前隐藏的人类蛋白质组，重新定义了疾病的靶向方式；这些隐秘蛋白是常规和下一代测序技术未能发现的。公司依托其专有的测序和人工智能平台RyboCypher™，揭示并验证新颖的、疾病特异性的隐秘靶点，从而推动针对癌症和其他具有高度未满足医疗需求的疾病的首创抗体疗法开发。

With proprietary IP licensed from Oregon Health & Science University, Knight Cancer Institute, RyboDyn is advancing a differentiated 'targets-to-assets' approach to therapeutic development. The company is based at Lilly Gateway Labs in San Diego and is a member of Lilly's AI TuneLabs consortium and NVIDIA's Inception Program, and has publicly disclosed a strategic collaboration with Moffitt Cancer Center..

RyboDyn 公司从俄勒冈健康与科学大学、奈特癌症研究所获得专有知识产权授权，正在推进一种差异化“从靶点到资产”的治疗开发方法。该公司位于圣地亚哥的礼来Gateway实验室，是礼来AI TuneLabs联盟和NVIDIA Inception计划的成员，并已公开披露与莫菲特癌症中心的战略合作。

RyboDyn is backed by leading global investors, including Genedant, SeaX Ventures, SOSV, Swell VC, Massive Tech Ventures, and P2V. The company was founded by serial entrepreneurs with prior venture-backed exits, including leadership roles in companies that achieved multi-billion-dollar public offerings and acquisitions..

RyboDyn 得到了包括 Genedant、SeaX Ventures、SOSV、Swell VC、Massive Tech Ventures 和 P2V 在内的全球领先投资者的支持。该公司由连续创业者创立，他们之前曾有过风险投资支持的成功退出经历，并在实现数十亿美元首次公开募股和收购的公司中担任过领导职务。

Media Contact

媒体联系人

Andy Bass

安迪·贝斯

VP, Corporate Strategy

副总裁，企业战略

[email protected]

电子邮件地址

SOURCE RyboDyn

源代码 RyboDyn

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示